The use of atypical antipsychotics and the risk of breast cancer

Breast Cancer Research and Treatment

Volumn 129, Issue 2, 2011, Pages 541-548

  Azoulay, Laurent ^a,b   Yin, Hui ^a   Renoux, Christel ^a   Suissa, Samy ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Antipsychotics; Breast cancer; Population based

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENPERIDOL; CHLORPROMAZINE; CLOZAPINE; DROPERIDOL; FLUPENTIXOL; FLUPHENAZINE; FLUSPIRILENE; HALOPERIDOL; LEVOMEPROMAZINE; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; OXYPERTINE; PERICIAZINE; PERPHENAZINE; PIMOZIDE; PIPOTIAZINE; PROMAZINE; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SERTINDOLE; SULPIRIDE; THIORIDAZINE; TRIFLUPERIDOL; UNINDEXED DRUG; ZOTEPINE;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; DRUG EXPOSURE; DRUG USE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GREAT BRITAIN; HUMANS; INCIDENCE; LOGISTIC MODELS; MIDDLE AGED; PATIENT SAFETY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 80052636167     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1506-2     Document Type: Article

References (28)

1. S Alessi-Severini RG Biscontri DM Collins A Kozyrskyj J Sareen, et al. 2008 Utilization and costs of antipsychotic agents: a Canadian population-based study, 1996-2006 Psychiatr Serv 59 547 553 18451015 10.1176/appi.ps.59.5.547
2. DL Leslie S Mohamed RA Rosenheck 2009 Off-label use of antipsychotic medications in the department of Veterans Affairs health care system Psychiatr Serv 60 1175 1181 19723731 10.1176/appi.ps.60.9.1175
3. DB Allison JL Mentore M Heo LP Chandler JC Cappelleri, et al. 1999 Antipsychotic-induced weight gain: a comprehensive research synthesis Am J Psychiatry 156 1686 1696 10553730 1:STN:280:DC%2BD3c%2FhvFWmug%3D%3D (Pubitemid 29517559)
4. JR Bostwick SK Guthrie VL Ellingrod 2009 Antipsychotic-induced hyperprolactinemia Pharmacotherapy 29 64 73 19113797 10.1592/phco.29.1.64 1:CAS:528:DC%2BD1MXhsl2it7k%3D
5. CH Miller F Mohr D Umbricht M Woerner WW Fleischhacker, et al. 1998 The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics J Clin Psychiatry 59 69 75 9501888 10.4088/JCP.v59n0205 1:CAS:528:DyaK1cXhvFGksbY%3D (Pubitemid 28141238)
6. PS Wang AM Walker MT Tsuang EJ Orav RJ Glynn, et al. 2002 Dopamine antagonists and the development of breast cancer Arch Gen Psychiatry 59 1147 1154 12470131 10.1001/archpsyc.59.12.1147 1:CAS:528:DC%2BD38XpslejsLw%3D (Pubitemid 35424025)
7. PM Haddad A Wieck 2004 Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management Drugs 64 2291 2314 15456328 10.2165/00003495-200464200-00003 1:CAS:528:DC%2BD2cXpvVyrtrk%3D (Pubitemid 39388605)
8. P Seeman 2002 Atypical antipsychotics: mechanism of action Can J Psychiatry 47 27 38 11873706 (Pubitemid 34302921)
9. C Bushe M Shaw RC Peveler 2008 A review of the association between antipsychotic use and hyperprolactinaemia J Psychopharmacol 22 46 55 18477620 10.1177/0269881107088435
10. JE Overall 1978 Prior psychiatric treatment and the development of breast cancer Arch Gen Psychiatry 35 898 899 678041 1:STN:280:DyaE1c3jsVGhtw%3D%3D (Pubitemid 9076804)
11. S Wagner N Mantel 1978 Breast cancer at a psychiatric hospital before and after the introduction of neuroleptic agents Cancer Res 38 2703 2708 679174 1:STN:280:DyaE1c3jslSjsQ%3D%3D (Pubitemid 9001510)
12. JP Kelly L Rosenberg JR Palmer RS Rao BL Strom, et al. 1999 Risk of breast cancer according to use of antidepressants, phenothiazines, and antihistamines Am J Epidemiol 150 861 868 10522657 1:STN:280: DyaK1MvltVCqsA%3D%3D (Pubitemid 29482839)
13. SO Dalton C Johansen AH Poulsen M Norgaard HT Sorensen, et al. 2006 Cancer risk among users of neuroleptic medication: a population-based cohort study Br J Cancer 95 934 939 16926836 10.1038/sj.bjc.6603259 1:STN:280:DC%2BD28rosVGhsA%3D%3D (Pubitemid 44498111)
14. J Hippisley-Cox Y Vinogradova C Coupland C Parker 2007 Risk of malignancy in patients with schizophrenia or bipolar disorder: nested case-control study Arch Gen Psychiatry 64 1368 1376 18056544 10.1001/archpsyc.64.12.1368 (Pubitemid 350223554)
15. T Walley A Mantgani 1997 The UK General Practice Research Database Lancet 350 1097 1099 10213569 10.1016/S0140-6736(97)04248-7 1:STN:280: DyaK1M3ivVGrsQ%3D%3D (Pubitemid 27437871)
16. LA Garcia Rodriguez GS Perez 1998 Use of the UK General Practice Research Database for pharmacoepidemiology Br J Clin Pharmacol 45 419 425 9643612 10.1046/j.1365-2125.1998.00701.x 1:STN:280:DyaK1czgsFOltw%3D%3D (Pubitemid 28227341)
17. H Jick SS Jick LE Derby 1991 Validation of information recorded on general practitioner based computerised data resource in the United Kingdom BMJ 302 766 768 2021768 10.1136/bmj.302.6779.766 1:STN:280:DyaK3M3hsFentQ%3D%3D
18. R Lawrenson T Williams R Farmer 1999 Clinical information for research; the use of general practice databases J Public Health Med 21 299 304 10528957 10.1093/pubmed/21.3.299 1:STN:280:DyaK1Mvls1ahtw%3D%3D (Pubitemid 29446069)
19. R Lawrenson JC Todd GM Leydon TJ Williams RD Farmer 2000 Validation of the diagnosis of venous thromboembolism in general practice database studies Br J Clin Pharmacol 49 591 596 10848723 10.1046/j.1365-2125.2000.00199.x 1:STN:280:DC%2BD3czgslejtA%3D%3D (Pubitemid 30326559)
20. SS Jick JA Kaye C Vasilakis-Scaramozza LA Garcia Rodriguez A Ruigomez, et al. 2003 Validity of the general practice research database Pharmacotherapy 23 686 689 12741446 10.1592/phco.23.5.686.32205 (Pubitemid 36539051)
21. L Opatrny S Dell'Aniello S Assouline S Suissa 2008 Hormone replacement therapy use and variations in the risk of breast cancer BJOG 115 169 175 18081598 1:STN:280:DC%2BD2sjksFygsg%3D%3D (Pubitemid 350233601)
22. DM Gardner AL Murphy H O'Donnell F Centorrino RJ Baldessarini 2010 International consensus study of antipsychotic dosing Am J Psychiatry 167 686 693 20360319 10.1176/appi.ajp.2009.09060802
23. SE Hankinson WC Willett DS Michaud JE Manson GA Colditz, et al. 1999 Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women J Natl Cancer Inst 91 629 634 10203283 10.1093/jnci/91.7.629 1:STN:280:DyaK1M3hsl2ntA%3D%3D (Pubitemid 29194050)
24. SS Tworoger AH Eliassen B Rosner P Sluss SE Hankinson 2004 Plasma prolactin concentrations and risk of postmenopausal breast cancer Cancer Res 64 6814 6819 15375001 10.1158/0008-5472.CAN-04-1870 1:CAS:528:DC%2BD2cXnsFOksbk%3D (Pubitemid 39297946)
25. SS Tworoger P Sluss SE Hankinson 2006 Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women Cancer Res 66 2476 2482 16489055 10.1158/0008-5472.CAN-05- 3369 1:CAS:528:DC%2BD28XhsFaltro%3D
26. SS Tworoger SE Hankinson 2008 Prolactin and breast cancer etiology: an epidemiologic perspective J Mammary Gland Biol Neoplasia 13 41 53 18246319 10.1007/s10911-008-9063-y
27. JA Lieberman TS Stroup JP McEvoy MS Swartz RA Rosenheck, et al. 2005 Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 353 1209 1223 16172203 10.1056/NEJMoa051688 1:CAS:528: DC%2BD2MXhtVeltL%2FN (Pubitemid 41345943)
28. R Rosenheck D Perlick S Bingham W Liu-Mares J Collins, et al. 2003 Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial JAMA 290 2693 2702 14645311 10.1001/jama.290.20.2693 1:CAS:528:DC%2BD3sXpsVaktLg%3D (Pubitemid 37475597)